About this trial
The study is a randomized, open, prospective phase II study. The aim of the study is to evaluate the safety and feasibility of a hypofractionated, accelerated radiation approach based on the incidence of grade 3-5 NCI Common Terminology Criteria for Adverse Events (NCI-CTC-AE ) toxicity and / or termination of the planned therapy for any reason with neoadjuvant radiation with active beam guidance of the retroperitoneal Sarcomas using protons or carbon ions before a subsequent tumor resection.
Eligibility criteria
Qualifiers
Histologically confirmed retroperitoneal soft-tissue sarcoma which is resectable or marginally resectable
Karnofsky index of ≥ 70%
Age from 18 years
Completed patient information and written consent
Disqualifiers
Stage IV (distant metastases)
Lymphogenic metastasis
Metal implants at the level of the sarcoma, which influence the treatment planning
Previous radiation therapy in the treatment area
Trial design
Treatments tested in this trial
- Proton radiation
- Carbon Ion radiation